PepGen Inc. Logo

PepGen Inc.

Biotech using an EDO platform to treat genetic neuromuscular & neurological diseases.

PEPG | NDAQ

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
United States of America
Address:
1 MARINA PARK DRIVE, SUITE 900, 2210 BOSTON
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

PepGen Inc. is a clinical-stage biotechnology company focused on developing a new generation of disease-modifying therapies. The company is creating a pipeline of therapeutics aimed at treating severe, genetic neuromuscular and neurological diseases by targeting their root cause. PepGen utilizes its proprietary Enhanced Delivery Oligonucleotide (EDO) platform to optimize the delivery of therapeutic oligonucleotides, with the goal of advancing transformative treatments for patients with devastating conditions.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all PepGen Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for PepGen Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for PepGen Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Advancing high-grade copper and precious metal projects from discovery to production.
Canada COR
Cantargia Logo
Develops antibody treatments targeting IL1RAP for cancer and autoimmune/inflammatory diseases.
Sweden CANTA
Captor Therapeutics S.A. Logo
Developing TPD therapeutics for oncology and autoimmune diseases with its Optigrade™ platform.
Poland CTX
Cardiff Oncology, Inc. Logo
Clinical-stage biotech developing a PLK1 inhibitor to treat resistant cancers.
United States of America CRDF
Cardio Diagnostics Holdings, Inc. Logo
AI-powered epigenetic and genetic tests for early detection of heart disease risk.
United States of America CDIO
Cardiol Therapeutics Inc. Logo
Develops oral cannabidiol therapies for inflammatory and fibrotic heart diseases.
United States of America CRDL
CareDx, Inc. Logo
Precision diagnostics and surveillance solutions for the organ transplant journey.
United States of America CDNA
Offers one-stop BPO, CRM, and staffing for admin, manufacturing, and logistics.
Japan 6070
Caris Life Sciences, Inc. Logo
Pioneering precision cancer care via AI-powered molecular profiling and diagnostics.
United States of America CAI
Carna Biosciences, Inc. Logo
Develops kinase inhibitor drugs for oncology/autoimmune diseases & offers discovery support services.
Japan 4572

Talk to a Data Expert

Have a question? We'll get back to you promptly.